Generic Medicine Info
Indications and Dosage
Infections due to Pseudomonas aeruginosa
Adult: Usual dose: 6 g daily in 4 divided doses; for less severe infections: 3-4 g daily may be used.
Child: Usual dose: 100 mg/kg daily; for less severe infections: 50 mg/kg daily.
Renal Impairment
In patients undergoing haemodialysis: 1 g is given before and after dialysis.
<5Loading dose: 1.5 g, then 1 g every 24 hr.
20-50Loading dose: 1.5 g, then 1 g every 8 hr.
5-20Loading dose: 1.5 g, then 1 g every 12 hr.
Hypersensitivity to cephalosporins.
Special Precautions
Hypersensitivity to penicillins; renal impairment; porphyria. Monitor renal and haematologic status.
Adverse Reactions
Nausea; vomiting; diarrhoea; hypersensitivity reactions; nephrotoxicity; convulsions; CNS toxicity; hepatic dysfunction; haematologic disorders; pain at inj site (IM); thrombophloebitis (IV infusion); superinfection with prolonged use.
Potentially Fatal: Pseudomembranous colitis.
Drug Interactions
Reduced renal clearance when used with probenecid.
Potentially Fatal: Increased risk of nephrotoxicity when used with aminoglycosides or loop diuretics.
Description: Cefsulodin has a narrow spectrum of activity. It is active against P. aeruginosa (which can be enhanced by aminoglycosides) but no significant activity against other gram-negative bacteria. Gram-positive bacteria and anaerobes are not very susceptible. It is also stable to hydrolysis by many β-lactamases.
Distribution: Up to 30% bound to plasma proteins.
Excretion: Plasma half-life of about 1.6 hr; prolonged in renal impairment. Mainly excreted via urine.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Cefsulodin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in